IG Health Data - RDA 13th Plenary Meeting

You are here

10 January 2019 980 reads

Meeting title: Data sharing challenges in biomedical Artificial Intelligence (AI) (Remote Access Instructions)


Meeting Location: Commonwealth C


Collaborative session notes: https://docs.google.com/document/d/1r82-fdK5G2RuunL5bZoUO84IJ9UwxdLlP3rtNccKQzY/edit


Short introduction describing the scope of the group and if any previous activities:

The Health Data Interest Group (HDIG) was officially instituted in 2016 following successful BoF Sessions during the 6th RDA Plenary Meeting in Paris and the 7th RDA Plenary Meeting in Tokyo. It is now a mature RDA component, actively involved in the 8th RDA Plenary Meeting in Denver with a session titled “Health Data Privacy & Security issues”, at P9 in Barcelona with a session focused on “Meaningful health data for research and for industry” at P10 in Montreal with a session on “Health data mapping and diverging trends in health data protection”, at P11 in Berlin on “First results on RDA Adoption and Training Guide for Reproducible Data Service Workflows and diverging trends in Health data protection” and at P12 in Gaborone, Botswana, where the topic of “Genomic data in the light of privacy rules” was addressed. 
All sessions were attended by several researchers and professionals from diverse backgrounds, who discussed a number of relevant issues as the Health Data IG is the only RDA group focusing on the intricacies of Health Data, especially as it relates to privacy and security issues in Healthcare. 
The Health Data IG sessions offer new topics, which are gaining interest for scientific research communities especially after the of the EU General Data Protection Regulation (GDPR). The topics can be debated within a wider and competent audience and with a worldwide perspective.

As a result, two working groups (WG) are spreading from the HDIG, one on “Blockchain Applications in Health”, which just completed the TAB review process and already had a couple of official meetings at P11 and P12, and another one on “Reproducible Health Data Services”, ongoing its approval process.

The next P13 in Philadelphia will be an occasion for HDIG members to discuss another relevant and up-to-date issue in the medical sector, focusing on AI medicine: preconditions to apply AI to biomedicine and privacy concerns (after the EU GDPR).


Additional links to informative material related to the group:

• Group page: https://rd-alliance.org/groups/health-data.html 
• Case statement: https://www.rd-alliance.org/group/health-data/case-statement/health-data...
• HDIG Sessions Presentations @RDA Plenaries (HDIG File Repository): https://www.rd-alliance.org/node/50708/repository 
• Draft Report on Diverging Trends in Health Data Protection (open to contribution): https://docs.google.com/document/d/130sL5lRRZlCjd-u-pTV7rJs5pSanc9WYemyp...


Meeting objectives:

Technologies and infrastructures for implementing biomedical Artificial Intelligence (AI) applications in clinical care are becoming ever more accessible and robust, but these systems are still held back by data scarcity, which increases development and clinical validation costs. Europe has taken an unprecedented step in clearing the data privacy landscape, but a variety of solutions exist to efficiently and securely share data in diverse contexts. This session will provide an in-depth overview of such solutions and provide practical insights to identify appropriate ones for different use cases.

The objectives of the meeting are:
1) To present and discuss challenges and opportunities related to data for medical-AI, regulatory frameworks and emergent data sharing solutions 
2) To discuss international concerns and needs regarding GDPR outside the EU.
(A white paper or position paper could be foreseen as a further output of the meeting).


Meeting agenda:

Brief introduction to the group 
Presentation (Guest speakers) on AI biomedicine: 
- What is AI and how is it used in biomedicine
- Preconditions to apply AI to biomedicine and privacy concerns (after the EU GDPR)
- Potential solutions to access and sharing data for AI development (for example, using simulated data or non-human data; anonymized data; de-identified data, when necessary)
Open debate
Next steps


Target audience:

For this open session, we invite Policymakers for Healthcare; Clinicians wanting to use data technology to improve their practice; Biomedical researchers using data-driven analytical techniques in their research life-cycle; Healthcare Data Scientists dealing with data mining, machine learning, physiological modelling and image processing technologies and the data these produce; Health bioinformatics legal experts; Healthcare and Health Maintenance Organization administrators; Pharmaceutical industry researchers and manufacturers; Medical equipment researchers and manufacturers, in silico modelling, testing and clinical trial experts; and, participants form other related WG/IG.


Group chair serving as contact person: Edwin Morley-Fletcher


Type of meeting: Working meeting